We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App

Abbott Showcases Next-Generation Alinity Family of Systems at AACC 2020 Virtual Event

By LabMedica International staff writers
Posted on 15 Dec 2020
Print article
Image: Alinity Family of Systems (Photo courtesy of Abbott)
Image: Alinity Family of Systems (Photo courtesy of Abbott)
Abbott (Lake Forest, IL, USA) showcased leading-edge technology at its virtual booth at 2020 AACC Annual Scientific Meeting with demonstrations of the company’s innovative systems, automation and informatics.

At the all virtual 2020 AACC held on December 13-17, Abbott demonstrated its next-generation Alinity family of systems across key laboratory disciplines designed to simplify diagnostics and help deliver results that drive better patient outcomes. Attendees to Abbott’s virtual booth experienced the company’s Alinity ci-series integrated clinical chemistry and immunoassay system, the Alinity h-series integrated hematology system and the Alinity m molecular system.

The Alinity series helps to easily adapt to the unpredictability of changing laboratory volume with scalable systems and multiple track connectivity options across Alinity platforms. The flexible, scalable systems allow easy addition of modules as lab volume grows over time, without having to replace any system. And with open automation and IT connectivity options such as Instrument Manager and AlinIQ BIS, a personalized solution can be designed for the entire laboratory. All this helps labs respond to the changing needs of the market and the community.

Alinity leverages powerful technology to redefine and improve operational productivity in the laboratory. Alinity allows users to more efficiently and effectively address limited space and increasing demand in their laboratory. Alinity has been designed to maximize the throughput in a more compact footprint. Additionally, Alinity allows staff more walkaway time, so they can focus on other critical tasks.

Alinity helps labs continually provide consistent, high-quality service and results through error-proof design elements and proven technology that minimize the frustration of repeat testing, system downtime, and medical errors. Additionally, labs can rely on Abbott’s high-quality assays with proven technology harmonized to CLSI guidelines, ensuring clear performance parameter definitions. And with predictive system monitoring through AlinIQ Always On, Abbott’s professional services can proactively monitor the health of the systems and help labs avoid unexpected downtime.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: ‘Virtual biopsy’ allows clinicians to analyze skin noninvasively (Photo courtesy of Stanford Medicine)

Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.